Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valneva Bounces Back From UK Snub With EU COVID-19 Vaccine Deal

Will Supply Up To 60 Million Doses.

Executive Summary

The European Commission has approved a purchase deal for Valneva’s COVID-19 vaccine candidate just months after the UK scrapped its own deal with the firm.

You may also be interested in...



Stock Watch: Dam Cracks After A Trickle Of Failed Pandemic Products

Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?

UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back

The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.

Valneva Advances New Vaccines Agenda With Top-Line Phase III Chikungunya Data

France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel